CHAMPIONS ONCOLOGY, INC.
CSBR · XNASCIK 771856fmd_1E1P4NKQAX1HGZZJ2N19KTGG2JManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: May 01, 2010 to Jul 31, 2026, 65 periods
Latest annual · FY2026
Millions- Total revenues
- 59
- Gross profit
- 29
- Operating income
- (1)
- Net income
- (1)
- Free cash flow
- (5)
Latest quarter · Q1 FY2027
Millions- Total revenues
- 15
- Gross profit
- 8
- Operating income
- (0)
- Net income
- (0)
- Free cash flow
- (1)
Daily close · CSBRIEX trades only
Nov 22, 2024 to Nov 10, 2026 · 250 sessions4.88 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2023 to FY2026
- +3.3%
- Revenue, 5 yearsFY2021 to FY2026
- +7.7%
- Net income, 5 yearsFY2021 to FY2026
- n/m
CHAMPIONS ONCOLOGY, INC. (CSBR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Revenue | $59.4 million | $56.9 million | +4.4% | 10-K 2026-07-27 · proof |
| Gross profit | $28.5 million | $28.6 million | -0.1% | 10-K 2026-07-27 · proof |
| Operating income | -$1.1 million | $4.6 million | -125% | 10-K 2026-07-27 · proof |
| Net income | -$1.2 million | $4.7 million | -125% | 10-K 2026-07-27 · proof |
| Cash from operating activities | -$4.5 million | $7.4 million | -160.5% | 10-K 2026-07-27 · proof |
| Free cash flow | -$5 million | $7 million | -172% | 10-K 2026-07-27 · proof |
| Total assets | $27 million | $32.3 million | -16.6% | 10-K 2026-07-27 · proof |
| Total liabilities | $22.9 million | $28.6 million | -19.8% | 10-K 2026-07-27 · proof |
| Cash and cash equivalents | $4.9 million | $9.8 million | -50.2% | 10-K 2026-07-27 · proof |
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s revenue in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported revenue of $59.4 million for fiscal 2026 (the year ended Apr 30, 2026), against $56.9 million the year before (+4.4%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s gross profit in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported gross profit of $28.5 million for fiscal 2026 (the year ended Apr 30, 2026), against $28.6 million the year before (-0.1%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s operating income in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported operating income of -$1.1 million for fiscal 2026 (the year ended Apr 30, 2026), against $4.6 million the year before (-125%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s net income in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported net income of -$1.2 million for fiscal 2026 (the year ended Apr 30, 2026), against $4.7 million the year before (-125%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s cash from operating activities in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported cash from operating activities of -$4.5 million for fiscal 2026 (the year ended Apr 30, 2026), against $7.4 million the year before (-160.5%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What was CHAMPIONS ONCOLOGY, INC. (CSBR)'s free cash flow in fiscal 2026?
- CHAMPIONS ONCOLOGY, INC. (CSBR) reported free cash flow of -$5 million for fiscal 2026 (the year ended Apr 30, 2026), against $7 million the year before (-172%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What are CHAMPIONS ONCOLOGY, INC. (CSBR)'s total assets?
- As of Apr 30, 2026, CHAMPIONS ONCOLOGY, INC. (CSBR) reported total assets of $27 million, against $32.3 million a year earlier (-16.6%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What are CHAMPIONS ONCOLOGY, INC. (CSBR)'s total liabilities?
- As of Apr 30, 2026, CHAMPIONS ONCOLOGY, INC. (CSBR) reported total liabilities of $22.9 million, against $28.6 million a year earlier (-19.8%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
- What are CHAMPIONS ONCOLOGY, INC. (CSBR)'s cash and cash equivalents?
- As of Apr 30, 2026, CHAMPIONS ONCOLOGY, INC. (CSBR) reported cash and cash equivalents of $4.9 million, against $9.8 million a year earlier (-50.2%). Source: the 10-K filed with the SEC on Jul 27, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CSBR&period_type=annual&limit=5"Information only, not investment advice.